Overview

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not P

Status:
Active, not recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal
BB 1101
Bortezomib
Daratumumab
Dexamethasone
Dexamethasone acetate
Lenalidomide
Thalidomide